MAGEA1 inhibits the expression of BORIS via increased promoter methylation

Zhao, Jizhong; Wang, Yueqing; Liang, Qianjin; Xu, Yan; Sang, Jianli

doi:10.1242/jcs.218628

Cited by 6 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, we speculate that Caspase3 protein. This is consistent with that BORIS knockdown can induce apoptosis of breast cancer cells 39 and BORIS can inhibit apoptosis of colorectal cancer cells. 40 These results indicate that SF2 (C2/A4) promotes the malignant development of liver cancer by inducing EMT.…”

Section: Discussionsupporting

confidence: 90%

BORIS variant SF2(C2/A4) promotes the malignant development of liver cancer by activating epithelial‐mesenchymal transition and hepatic stellate cells

Wei

Liu

Qin

et al. 2023

Molecular Carcinogenesis

View full text Add to dashboard Cite

The underlying mechanisms of metastasis and recurrence of liver cancer remain largely unknown. Here, we found that Brother of the Regulator of Imprinted Sites (BORIS) variant SF2(C2/A4) was highly expressed in high metastatic potential hepatocellular carcinoma (HCC) cells and clinical tumor samples, related to the formation of satellite nodules. Its over expression promoted self-renewal, the expression of tumor stem cell markers, chemoresistance, wound healing rate, invasion and metastasis of HepG2 and Hep3B cells; reinforced epithelialmesenchymal transition (EMT), decreased the expression of E-cadherin and increased N-cadherin and Vimentin. Subcellular localization experiment showed that BORIS SF2(C2/A4) was localized in nucleus and cytoplasm. Further double luciferase reporter gene experiment confirmed that it bound to TWIST1 gene promoter and significantly increased latter expression. BORIS SF2(C2/A4) knock down induced apoptosis of HCCLM3 and PLC/PRF/5 cells, and increased the protein content of cleaved caspase 3. Additionally, BORIS SF2(C2/A4) over expression increased the expression of fibroblast growth factor 2 (FGF2) in HepG2 and Hep3B cells. FGF2 expressed higher in HCC tumor tissues than in paired peritumor tissues, and its expression was positively correlated with BORIS SF2(C2/A4).Interestingly, high expression of FGF2 is also associated with the formation of satellite nodules. Moreover, using the medium from BORIS SF2(C2/A4) overexpressed cell lines to coculture hepatic stellate cell (HSCs) line LX-2, the latter could be activated and increased the expression of CD90 and PIGF, which is consistent with the effect of adding bFGF alone. These results indicate that BORIS SF2(C2/A4) plays a role in deterioration of liver cancer by regulating TWIST1 to induce EMT, and by FGF2 to activate HSCs.

show abstract

Section: Discussionsupporting

confidence: 90%

BORIS variant SF2(C2/A4) promotes the malignant development of liver cancer by activating epithelial‐mesenchymal transition and hepatic stellate cells

Wei

Liu

Qin

et al. 2023

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…Evidence shows that 5-aza-2′-CdR can regulate the expression of CTCFL (also known as BORIS ), a transcriptional regulator that may be responsible for the regulation of numerous CT genes [ 38 , 39 , 40 ]. At this time, it is unknown whether the SSX1 , SSX2 , and SSX3 gene expression alterations induced by 5-aza-2′-CdR are due to alterations in the methylation at the position of their promoter or in the expressions of other transcription factors, such as CTCFL , which may regulate SSX gene expressions.…”

Section: Discussionmentioning

confidence: 99%

Higher Expression Levels of SSX1 and SSX2 in Patients with Colon Cancer: Regulated In Vitro by the Inhibition of Methylation and Histone Deacetylation

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: Colon cancer (CC) has a high mortality rate and is often diagnosed at an advanced stage in Saudi Arabia. Thus, the identification and characterization of potential new cancer-specific biomarkers are imperative for improving the diagnosis of CC by detecting it at an early stage. Cancer-testis (CT) genes have been identified as potential biomarkers for the early diagnosis of various cancers. Among the CT genes are those belonging to the SSX family. In order to assess the usefulness of SSX family genes as cancer biomarkers for the detection of early-stage CC, the goal of this research was to validate the expressions of these genes in patients with CC and in matched patients with normal colons (NCs). Materials and Methods: RT-PCR assays were used to analyze the SSX1, SSX2, and SSX3 family gene expression levels in 30 neighboring NC and CC tissue samples from male Saudi patients. Epigenetic alterations were also tested in vitro using qRT-PCR analysis to determine whether reduced DNA methyltransferase or histone deacetylation could stimulate SSX gene expression via 5-aza-2′-deoxycytidine and trichostatin treatments, respectively. Results: The RT-PCR results showed SSX1 and SSX2 gene expression in 10% and 20% of the CC tissue specimens, respectively, but not in any of the NC tissue specimens. However, no SSX3 expression was detected in any of the examined CC or NC tissue samples. In addition, the qRT-PCR results showed significantly higher SSX1 and SSX2 expression levels in the CC tissue samples than in the NC tissue samples. The 5-aza-2′-deoxycytidine and trichostatin treatments significantly induced the mRNA expression levels of the SSX1, SSX2, and SSX3 genes in the CC cells in vitro. Conclusions: These findings suggest that SSX1 and SSX2 are potentially suitable candidate biomarkers for CC. Their expressions can be regulated via hypomethylating and histone deacetylase treatments, subsequently providing a potential therapeutic target for CC.

show abstract

“…Several MAGE proteins are unusually expressed in many cancer types. Zhao et al study showed that MAGEA1 expression is low or undetectable in several breast cancer cell lines ([ 42 ]. This study’s results resemble a great degree the current results regarding DDX43 under-expression in BC patients compared to normal subjects.…”

Section: Discussionmentioning

confidence: 99%

DDX43 mRNA expression and protein levels in relation to clinicopathological profile of breast cancer

et al. 2023

View full text Add to dashboard Cite

Background Breast cancer (BC) is the most often diagnosed cancer in women globally. Cancer cells appear to rely heavily on RNA helicases. DDX43 is one of DEAD- box RNA helicase family members. But, the relationship between clinicopathological, prognostic significance in different BC subtypes and DDX43 expression remains unclear. Therefore, the purpose of this study was to assess the clinicopathological significance of DDX43 protein and mRNA expression in different BC subtypes. Materials and methods A total of 80 females newly diagnosed with BC and 20 control females that were age-matched were recruited for this study. DDX43 protein levels were measured by ELISA technique. We used a real-time polymerase chain reaction quantification (real-time PCR) to measure the levels of DDX43 mRNA expression. Levels of DDX43 protein and mRNA expression within BC patients had been compared to those of control subjects and correlated with clinicopathological data. Results The mean normalized serum levels of DDX43 protein were slightly higher in control than in both benign and malignant groups, but this result was non-significant. The mean normalized level of DDX43 mRNA expression was higher in the control than in both benign and malignant cases, although the results were not statistically significant and marginally significant, respectively. Moreover, the mean normalized level of DDX43 mRNA expression was significantly higher in benign than in malignant cases. In malignant cases, low DDX43 protein expression was linked to higher nuclear grade and invasive duct carcinoma (IDC), whereas high mRNA expression was linked to the aggressive types of breast cancer such as TNBC, higher tumor and nuclear grades. Conclusion This study explored the potential of using blood DDX43 mRNA expression or protein levels, or both in clinical settings as a marker of disease progression in human breast cancer. DDX43 mRNA expression proposes a less invasive method for discriminating benign from malignant BC.

show abstract

MAGEA1 inhibits the expression of BORIS via increased promoter methylation

Cited by 6 publications

References 38 publications

BORIS variant SF2(C2/A4) promotes the malignant development of liver cancer by activating epithelial‐mesenchymal transition and hepatic stellate cells

BORIS variant SF2(C2/A4) promotes the malignant development of liver cancer by activating epithelial‐mesenchymal transition and hepatic stellate cells

Higher Expression Levels of SSX1 and SSX2 in Patients with Colon Cancer: Regulated In Vitro by the Inhibition of Methylation and Histone Deacetylation

DDX43 mRNA expression and protein levels in relation to clinicopathological profile of breast cancer

Contact Info

Product

Resources

About